// App-Quantinova.ai

2533 : VE-BASKET, a first-in-kind, phase II, histology-independent "basket" study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m).

Researchers

Presenter

  • David Michael Hyman

Principal Investigators

  • Jean-Yves Blay

  • Juergen Wolf

  • Florin Sirzen

  • Maria Luisa Veronese

  • Lada Mitchell

  • Igor Puzanov

  • Jose Baselga

  • Ian Chau

  • Noopur S. Raje

  • Maria Elena Elez Fernandez

Medical Centers

  • University of Cologne, Cologne, DE, Germany

  • F. Hoffmann-La Roche, Basel, SwitzerlandHospital Vall dHebron, Barcelona, SpainVanderbilt University Medical Center, Nashville, TN

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Centre Leon Berard, Lyon, France

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Massachusetts General Hospital, Boston, MA

Locations

  • Germany

  • Switzerland

  • United Kingdom

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

Drug/Treatment

  • Vemurafenib

Outcome

  • Positive

Study Design

  • adaptive

Phase

  • NA

Study Id's

  • NCT01524978

Sponsors

  • Roche

  • Hoffmann-La Roche

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved